These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18242899)

  • 1. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism.
    Huang J; Si L; Jiang L; Fan Z; Qiu J; Li G
    Int J Pharm; 2008 May; 356(1-2):351-3. PubMed ID: 18242899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The inhibitory effect of pluronic on P-glycoprotein drug pump].
    Huang JG; Si LQ; Zuo KY; Wu XG; Qiu J; Li G
    Yao Xue Xue Bao; 2007 Sep; 42(9):989-94. PubMed ID: 18050744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism.
    Guan Y; Huang J; Zuo L; Xu J; Si L; Qiu J; Li G
    Arch Pharm Res; 2011 Oct; 34(10):1719-28. PubMed ID: 22076772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
    Batrakova EV; Li S; Miller DW; Kabanov AV
    Pharm Res; 1999 Sep; 16(9):1366-72. PubMed ID: 10496651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
    Eagling VA; Profit L; Back DJ
    Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats.
    Ma L; Wei Y; Zhou Y; Ma X; Wu X
    Arch Pharm Res; 2011 Nov; 34(11):1939-43. PubMed ID: 22139693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
    Patel J; Buddha B; Dey S; Pal D; Mitra AK
    Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
    Cummins CL; Jacobsen W; Benet LZ
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
    Iwanaga K; Hayashi M; Hamahata Y; Miyazaki M; Shibano M; Taniguchi M; Baba K; Kakemi M
    Drug Metab Dispos; 2010 Aug; 38(8):1286-94. PubMed ID: 20463004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.
    Mouly SJ; Paine MF; Watkins PB
    J Pharmacol Exp Ther; 2004 Mar; 308(3):941-8. PubMed ID: 14718607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells.
    Fan J; Maeng HJ; Du Y; Kwan D; Pang KS
    Eur J Pharm Sci; 2011 Jan; 42(1-2):19-29. PubMed ID: 20955791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
    Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
    J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
    Yalkinoglu Ö; Becker A; Krebs-Brown A; Vetter C; Lüpfert C; Perrin D; Heuer J; Biedert H; Hirt S; Bytyqi A; Bachmann A; Strotmann R
    Invest New Drugs; 2023 Aug; 41(4):596-605. PubMed ID: 37415001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability.
    Tan W; Chen H; Zhao J; Hu J; Li Y
    J Pharm Pharm Sci; 2008; 11(3):97-105. PubMed ID: 18801310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells.
    Seeballuck F; Ashford MB; O'Driscoll CM
    Pharm Res; 2003 Jul; 20(7):1085-92. PubMed ID: 12880295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.
    Tolle-Sander S; Rautio J; Wring S; Polli JW; Polli JE
    Pharm Res; 2003 May; 20(5):757-64. PubMed ID: 12751631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism.
    Kwatra D; Budda B; Vadlapudi AD; Vadlapatla RK; Pal D; Mitra AK
    Mol Pharm; 2012 Jul; 9(7):1877-86. PubMed ID: 22676443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
    Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
    J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.